Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.



Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

Diagnosis of medullary thyroid cancer and prognostic factors of disease aggressiveness

Cover Page

Abstract


In the study were enrolled 137 patients with medullary thyroid cancer (MTC). Low 35%-sensitivity of FNAC and high accuracy of basal calcitonin in MTC diagnostics were found. Mutation analysis of the RET pro- tooncogene in familial and sporadic MTC, RAS -gene in sporadic MTC were done. The correlation between type of the mutation and disease aggressiveness was found.

D O Gazizova

aspirant FGBU ENTs

D G Beltsevich

Email: beltsevich@rambler.ru
doktor med. nauk, gl. nauch. sotr. otd. khirurgii FGBU ENTs

A N Tiulpakov

doktor med. nauk, zav. otdeleniem nasledstvennykh endokrinopatiy FGBU ENTs

T V Soldatova

kand. med. nauk, zav. otdeleniem ul'trazvukovoy diagnostiki FGBU ENTs

A V Ilyin

zav. otdeleniem klinicheskoy biokhimii FGBU ENTs

  1. Cohen MS, Moley JF. Surgical treatment of medullary thyroid carcinoma. J Internal Med. 2003;253(6):616-626.
  2. Modigliani E, Cohen R, Campos JM et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a` calcitonine. Clin Endocrinol. 1998;48:265-273.
  3. Hahm JR, Lee MS, Min YK et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid. 2001;11:73-80.
  4. Elisei R, Bottici V, Luchetti F et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab. 2004; 89:163-168.
  5. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1-48.
  6. Kebebew E, Kikuchi S, Duh QY, Clark OH. Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg. 2000;135:895-901.
  7. Agrawal N, Jiao Y, Sausen M et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab. 2013;98(2):364-369.
  8. Ciampi R, Mian C, Fugazzola L et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid. 2013;23(1):50-57.
  9. Stepanas AV, Samaan NA, Hill CS, Hickey RC. Medullary thyroid carcinoma: importance of serial serum calcitonin measurement. Cancer. 1979;43:825-837.
  10. Fugazzola L, Pinchera A, Luchetti F et al. Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers. 1994;9:21-24.
  11. Sobin LH, Gospodarowicz MK, Wittekind Ch. TNM Classification of malignant Tumors, 7th ed. Wiley-Blackwell Oxford. 2009.
  12. Реброва ОЮ. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: Медиа Сфера, 2002. 312 с.
  13. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;83:2638- 2648.
  14. Pelizzo MR, Boschin IM, Bernante P et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol. 2007;33:493-497.
  15. Franc S, Niccoli-Sire P, Cohen R et al. Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol. 2001;55:403-409.
  16. Chambon G, Alovisetti C, Idoux-Louche C et al. The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: Results from 2733 consecutive patients. J Clin Endocrinol Metab. 2011;96(1):75-81.
  17. Beressi N, Campos JM, Beressi JP. Sporadic medullary microcarcinoma of the thyroid: a retrospective analysis of eighty cases. Thyroid. 1998;8:1039-1044.
  18. Hamy A, Pessaux P, Miralli e E. Central neck dissection in the management of sporadic medullary thyroid microcarcinoma. Eur J Surg Oncol. 2005;31:774-777.
  19. Kaserer K, Scheuba C, Neuhold N. Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of consecutive patients. Am J Surg Pathol. 2001;25:1245-1251.
  20. Ahmed SR, Ball DW. Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment. J Clin Endocrinol Metab. 2011;96:1237-1245.
  21. Кондратьева ТТ. Возможности цитологического метода в диагностике нетипичных вариантов рака щитовидной железы. Рак щитовидной железы. ESO RED SQUARE SEMINAR. М.: 2004:2931.
  22. Papaparaskeva K, Nagel H, Droese M. Cytologic diagnosis of medullary carcinoma of the thyroid gland. Diagn Cytopathol. 2000;22:351-358.
  23. Paszko Z, Sromek M, Czetwertynska M et al. The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindreds from Central Poland. Cancer Invest. 2007;25:742-749.
  24. Baloch ZW, LiVolsi VA. Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma. Thyroid. 2001;11:637-645.
  25. Frank-Raue K, Hoppner W, Frilling A et al. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin Endocrinol Metab. 1996;81(5):1780-1783.
  26. Romei C, Mariotti S, Fugazzola L et al. ItaMEN network, MEN 2: results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol. 2010;163(2):301-308.
  27. Schilling T, Burck J, Sinn H-P et al. Prognostic value of codon (ATG3ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer (Pred. Oncol.). 2001;95:62-66.
  28. Elisei R, Barbara Cosci B, Romei C et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10-year follow-up study. J Clin Endocrinol Metab. 2008;93:682-687.
  29. Marsh DJ, Learoyd DL, Andrew SD et al. Somatic mutations in the RET protooncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf). 1996;44:249-257.
  30. Goutas N, Vlachodimitropoulos D, Bouka M et al. MBRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res. 2008;28:305-308.
  31. Moura MM, Cavaco BM, Pinto AE et al. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer. 2009; 100(11):1777-1783.
  32. Dockhorn-Dworniczak B, Caspari S, Schroder S et al. Demonstration of activated oncogenes of the ras family in human thyroid tumors using the polymerase chain reaction. Verh Dtsch Gas Pathol. 1990;74:415-418.
  33. Wells SA, Robinson BG, Gagel RF et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial (ZETA). J Clin Oncol. 2012;30:134-141.

Views

Abstract - 829

PDF (Russian) - 1266


Copyright (c) 2013 ., ., ., ., .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.